Astrocytoma — Types, Symptoms, Diagnosis, Treatment and Prognosis

Most readers benefit from the Quick Summary plus the sections on Treatment, When Surgery Is Not Recommended, and Prognosis. The remaining sections provide deeper understanding.

This page focuses mainly on adult brain astrocytoma, especially IDH-mutant diffuse astrocytoma grades 2–4. Its main purpose is to help patients and families understand treatment decisions over time: when surgery is recommended, when biopsy or observation may be safer, when radiotherapy and Temozolomide are used, how MRI follow-up is interpreted, what recurrence or progression may mean, and how grade, molecular markers, seizures, functional status, and prior treatment shape prognosis.

What Is Astrocytoma?

Astrocytoma is a tumor that arises from astrocytic glial cells, a type of supportive cell in the brain. Glial cells normally help protect, nourish, and stabilize neurons (nerve cells). When astrocytic cells start to grow uncontrollably, they may form tumors with very different biological behaviors. Astrocytomas are one of the most common types of gliomas, a term frequently used in searches for brain tumors.

Astrocytomas can develop both in the brain and the spinal cord. For detailed information about spinal (intramedullary) astrocytomas, see: Intramedullary Spinal Cord Tumors.

From the patient’s perspective, the word astrocytoma can be misleading because it sounds like one diagnosis. In reality, it includes tumors that differ profoundly in:

• age group
• growth speed
• MRI appearance
• surgical strategy
• need for further treatment
• long-term prognosis

Some astrocytomas are relatively well circumscribed and behave in a more benign way. Others are diffuse gliomas, meaning they do not remain confined to a sharply defined mass, but infiltrate healthy brain tissue microscopically.

The classification used on this page follows the WHO CNS classification (World Health Organization Classification of Tumors of the Central Nervous System), an internationally accepted system that defines brain tumors based on both their microscopic appearance and molecular characteristics.

That is why a patient with a pilocytic astrocytoma and a patient with an astrocytoma, IDH-mutant, grade 4 do not in practice have the same disease, even though both tumors belong to the broad astrocytic family.

Gliomas as a group occur in approximately 4–6 cases per 100,000 people per year, with astrocytic tumors representing a substantial proportion of these cases.

This page focuses primarily on astrocytomas in adults. Pediatric astrocytomas represent a different group of diseases with distinct behavior and treatment principles.

How Many Types of Astrocytoma Exist?

According to the WHO classification, there are many distinct astrocytic tumor entities, reflecting different biological mechanisms, genetic alterations, and clinical behaviors.

In total, modern classifications recognize more than 20 different astrocytic and related tumor types, particularly when pediatric and rare tumors are included.

However, in adult clinical practice, most patients fall into a much smaller number of categories:

• Astrocytoma, IDH-mutant (grades 2–4)
• Glioblastoma, IDH-wildtype

This is why, although the classification appears complex, the majority of real-world treatment decisions are based on only a few key tumor types.

Why Astrocytomas Are Not a Single Disease

This is the single most important thing patients and families need to understand — astrocytoma is not one disease, but a group of biologically distinct tumors.

Older classifications focused mainly on how the tumor looked under the microscope and whether it was called low-grade, anaplastic, or glioblastoma. Modern classification goes further and combines:

• histology
• molecular markers
• clinical behavior

The most important molecular distinction in adult diffuse astrocytic tumors is IDH mutation status.

Why IDH Matters in Astrocytoma

Most genetic alterations make a tumor behave more aggressively. Interestingly, IDH mutation is one of the rare examples in oncology where a mutation may actually work partly in the patient’s favor. Tumors with IDH mutation usually grow more slowly and have a more favorable prognosis than comparable IDH-wildtype tumors (with a non-mutated IDH gene). To be classified as a diffuse astrocytoma in adults, regardless of grade (2–4), a tumor must have an IDH mutation.

For example:

• The highest grade 4 IDH-mutant astrocytoma is not the same disease as glioblastoma
• IDH-wildtype diffuse astrocytic tumors in adults are not classified as lower-grade astrocytomas. Even when classical high-grade histological features are absent, the presence of specific molecular alterations leads to their classification as glioblastoma (WHO grade 4).

Why Age Matters in Astrocytoma

Astrocytomas in children are often very different from astrocytomas in adults.

For example:

• many pediatric grade 1 astrocytomas may remain stable for years or be cured surgically
• adult diffuse astrocytomas usually infiltrate surrounding brain tissue and require a very different long-term strategy

For patients, the practical meaning is simple:

• the name on the pathology report
• the IDH status
• the MRI pattern
• and the clinical context

must always be interpreted together when making treatment decisions.

Astrocytomas in Children (Different Disease Group — Brief Context)

Astrocytic tumors in children represent a separate biological group and should not be directly compared with astrocytomas discussed later on this page.

In the current WHO CNS classification, pediatric gliomas are divided into several categories that include multiple distinct tumor entities, not a single disease.

These include:

• Pediatric-type diffuse low-grade gliomas
  → multiple tumor types (approximately 6–8 entities)
  → usually WHO grade 1–2
• Pediatric-type diffuse high-grade gliomas
  → several distinct tumor entities (around 4–6 types)
  → WHO grade 3–4
• Circumscribed astrocytic gliomas
  → 6 defined tumor types
  → most often WHO grade 1, but may include higher-grade variants

What This Means in Practice

• Pediatric astrocytic tumors include more than a dozen different tumor types overall
• They cover the full spectrum of WHO grades (1–4)
• They differ significantly in:
  • growth pattern
  • molecular biology
  • clinical behavior
  • treatment approach

Diffuse Astrocytoma in Adults (IDH-mutant, WHO Grades 2–4)

From this point onward, the discussion refers to astrocytomas in adults, which are predominantly diffuse infiltrative tumors with a different biology and clinical course compared to pediatric tumors.

In adults, the most clinically important astrocytic diffuse glioma group is Astrocytoma, IDH-mutant.

This is a biologically distinct family that includes:

• Grade 2 astrocytomas are often diagnosed in younger adults, commonly between 20–40 years
• Grade 3 astrocytomas tend to occur somewhat later, often in 30–50 years
• Grade 4 astrocytomas (IDH-mutant) are usually seen in adults between 30–60 years, although variability exists

These tumors usually arise through a pathway that is different from glioblastoma. They tend to occur in younger adults and often have a longer clinical course.

What “Diffuse” Means — Why These Tumors Grow Infiltratively

From a clinical perspective, diffuse astrocytomas do not grow as neatly encapsulated masses with sharp borders. Instead, they infiltrate the surrounding brain microscopically. In practical terms, this means that the visible tumor on MRI is not the entire disease.

Like a fog extending beyond the visible core, tumor cells may spread into surrounding tissue that appears only mildly abnormal or even normal on standard imaging.

This infiltrative behavior explains why surgery alone often cannot eradicate the disease completely, even when the visible lesion is removed very extensively.

Image: Illustrating diffuse brain infiltration by an astrocytoma. This microscopic spread makes it impossible to define a precise boundary between the tumor and healthy tissue during surgical resection.

Grade 2 IDH-mutant Astrocytoma in Adults

Grade 2 tumors usually have a slower growth rate, but they are still diffuse gliomas and are not benign in the practical surgical sense.

Patients may present with:

• seizures
• headaches
• subtle cognitive change
• focal neurological symptoms
• or an incidental MRI finding

These tumors may remain clinically stable for prolonged periods, but recurrence after surgery or progression over time is common.

Grade 3 IDH-mutant Astrocytoma

Grade 3 disease generally reflects a more active and biologically aggressive phase of the same tumor family.

Compared with grade 2, grade 3 tumors typically show:

• higher proliferative activity (meaning the tumor cells are dividing and growing more rapidly)
• faster growth
• greater likelihood of progression
• greater need for postoperative oncologic treatment

For patients, the key point is that grade 2 and grade 3 do not represent two unrelated diseases, but rather different levels of aggressiveness within the same IDH-mutant astrocytoma spectrum.

Grade 4 IDH-mutant Astrocytoma

Grade 4 astrocytoma with IDH mutation represents the most aggressive end of this same spectrum, but it still remains biologically distinct from glioblastoma.

This distinction is not just academic. It has real consequences for:

• expected survival
• treatment interpretation
• counseling

Grade 4 Astrocytoma: IDH-mutant vs Glioblastoma

This distinction is one of the most important modern concepts in neuro-oncology.

Astrocytoma, IDH-mutant, grade 4 is not the same disease as glioblastoma, IDH-wildtype. Glioblastoma refers specifically to a highly aggressive IDH-wildtype diffuse astrocytic tumor with grade 4 biology.

Although both are grade 4 tumors, the biology is different. In general IDH-mutant grade 4 astrocytoma usually has a better prognosis.

IDH-wildtype diffuse astrocytic tumors in adults are not classified as lower-grade astrocytomas. When specific molecular features associated with glioblastoma are present, they are classified as glioblastoma (WHO grade 4), even in the absence of classic high-grade histological features. In some cases, a tumor may be IDH-wildtype but not yet meet full criteria for glioblastoma on initial analysis. Further molecular testing and follow-up are then required to establish the final diagnosis.

Bottom Line

• Grade 4 IDH-mutant astrocytoma = an astrocytoma, biologically distinct from GBM
• Glioblastoma = usually IDH-wildtype, highly aggressive diffuse astrocytic tumor

How Astrocytoma Develops: Genetic Mutations and Tumor Biology

Astrocytoma develops as a consequence of acquired (mutations that occur during a person’s lifetime, not inherited from parents) genetic mutations that disrupt the normal regulation of cell growth, differentiation, and survival. As these mutations accumulate over time, tumor cells gradually lose normal control mechanisms and begin to behave independently of surrounding brain tissue.

These gene mutations involve two fundamental biological processes:

• activation of oncogenic pathways (driving uncontrolled proliferation)
• loss of tumor suppressor function (removing normal growth inhibition)

In astrocytoma, this process is not uniform. The biological behavior of the tumor depends strongly on its molecular profile, rather than on histological appearance alone.

The most important molecular distinction is:

• IDH-mutant astrocytoma
• versus IDH-wildtype diffuse astrocytic tumors

IDH-mutant astrocytomas typically arise through a slower evolutionary pathway. Tumor cells accumulate mutations gradually, and the disease often follows a prolonged clinical course over years.

In contrast, IDH-wildtype tumors (which are usually classified as glioblastoma when aggressive features are present) tend to follow a more rapid and biologically aggressive trajectory.

In addition to IDH, other molecular alterations may be identified (ATRX loss, TP53 mutations, proliferation indices such as Ki-67), but their clinical relevance varies. Some markers are used primarily to confirm the tumor type, while others help estimate growth potential.

It is important for patients to understand:

• these mutations are not inherited in the vast majority of cases
• they occur spontaneously during life
• they reflect errors in DNA replication or repair

Astrocytoma is therefore not caused by a single event, but by a progressive accumulation of molecular changes that gradually shift cells from normal regulation toward uncontrolled, malignant growth.

In rare cases, astrocytomas may develop as part of inherited genetic conditions. These include disorders such as neurofibromatosis type 1 (NF1), Li-Fraumeni syndrome, and tuberous sclerosis complex, which are associated with an increased risk of certain brain tumors. However, this situation is uncommon, and the vast majority of astrocytomas occur sporadically, without any inherited predisposition.

Influence of External Factors on Astrocytoma

The role of external factors in the development of astrocytoma is often misunderstood.

Current scientific evidence indicates:

• High-dose ionizing radiation (for example, previous radiation therapy to the head) is the only well-established environmental risk factor
• most astrocytomas arise sporadically, without an identifiable external trigger

Several commonly discussed factors are not supported by consistent evidence:

• mobile phone use
• psychological stress
• head trauma
• lifestyle factors

These are frequently mentioned by patients but have not been proven to directly cause astrocytoma.

Other factors are under investigation:

• long-term inflammation
• viral influences
• occupational exposures

However, their role remains uncertain and is not considered causative in routine clinical practice.

From a practical standpoint, the key message is:

• astrocytoma is primarily driven by internal genetic alterations, not by lifestyle or daily habits

This distinction is important because many patients incorrectly assume that something they did caused the disease.

Mechanisms of Brain Damage in Astrocytoma

Astrocytoma affects brain function through several mechanisms, which often occur simultaneously:

Tumor Infiltration of Functional Brain Tissue

Diffuse astrocytomas infiltrate areas responsible for movement, speech, vision, and cognition. As tumor cells invade these networks, neurological deficits develop.

These deficits depend on tumor location and may include:

• weakness in the opposite side extremities
• speech impairment
• visual disturbances
• cognitive decline

Image: Functional centers in the brain cortex. Explanations regarding the anatomy of various brain regions can be found on this page.

Peritumoral Edema and Increased Intracranial Pressure

Tumor-associated swelling (edema) is a major contributor to symptoms.

Disruption of the blood–brain barrier leads to fluid leakage into surrounding tissue, resulting in:

• increased intracranial pressure
• headache
• nausea
• neurological deterioration

Corticosteroids (such as Dexamethasone) may temporarily improve symptoms by reducing this edema. Before corticosteroids are given, it is important to consider whether primary CNS lymphoma is a possibility, as steroids can rapidly reduce or even obscure the lesion and complicate diagnosis.

Mass Effect and Secondary Complications

As tumor volume and edema increase, pressure effects develop:

• compression of brain structures
• displacement of midline structures
• obstruction of cerebrospinal fluid flow (hydrocephalus)

In severe cases, this may lead to life-threatening brain shifts (herniation).

Functional Network Disruption

Even without massive tumor growth, infiltration of neural networks can lead to:

• cognitive slowing
• personality change
• loss of executive function

This explains why some patients deteriorate even when imaging does not show dramatic enlargement.

Functional Status and Karnofsky Performance Scale (KPS)

In astrocytoma, symptoms alone are not sufficient to guide treatment decisions. Equally important is the patient’s functional status, which reflects the ability to perform daily activities.

The most widely used tool is the Karnofsky Performance Status (KPS).

It plays a central role, especially in patients with grade 4 astrocytoma, in determining:

• suitability for surgery
• tolerance of radiotherapy and chemotherapy
• expected recovery
• overall prognosis

Karnofsky Scale (Simplified)

• 90–100 → normal or near normal function
• 70–80 → independent but limited
• 50–60 → requires assistance
• <50 → severe disability

A higher KPS generally indicates:

• better tolerance of treatment
• better functional recovery potential
• more favorable prognosis

It is important to understand:

• KPS does not measure tumor biology directly
• it reflects the impact of the tumor on the patient

In many cases, improvement after corticosteroids suggests that symptoms are driven by edema rather than irreversible damage, which may influence surgical decisions.

How Astrocytoma Behaves Over Time

Unlike glioblastoma, which often progresses rapidly, many astrocytomas — especially IDH-mutant tumors — follow a prolonged clinical course.

However, progression over time is expected, not exceptional.

The disease typically evolves through phases:

• initial diagnosis (often slower-growing stage)
• period of relative stability
• gradual progression
• possible transformation to higher-grade disease

Progression may present as:

• growth on MRI
• worsening neurological symptoms
• increased contrast enhancement
• new or worsening edema

It is important to understand:

• stability does not mean cure
• progression may occur after years of apparent control
• long-term follow-up is essential

The key clinical challenge is not only detecting progression, but determining when intervention is beneficial.

Symptoms of Astrocytoma in Adults

Symptoms depend mainly on:

• tumor location
• tumor growth speed
• degree of infiltration
• presence of edema
• intracranial pressure
• and whether seizures occur

Common Symptoms

• headache
• seizures
• focal neurological deficits
• speech problems
• weakness in the opposite side extremities
• visual symptoms
• cognitive decline
• personality or behavioral changes
• gait instability

How Astrocytoma in Adults Is Diagnosed

MRI Is the Key Imaging Study

Magnetic resonance imaging (MRI) of the brain, performed with and without contrast, is the central diagnostic test when astrocytoma is suspected.

MRI helps define:

• tumor location
• size
• growth pattern
• involvement of eloquent brain regions
• heterogeneous contrast enhancement
• central necrotic change
• edema
• mass effect (compression on the brain)
• ventricular compression
• hemorrhage
• and overall surgical accessibility

Different astrocytomas have different imaging appearances. A crucial principle for patients to understand is this the visible lesion on MRI is not always the whole disease. In diffuse astrocytomas, microscopic tumor cells extend beyond the obvious borders.

In addition to defining anatomy and surgical accessibility, MRI findings must always be interpreted in the context of tumor biology. In IDH-mutant astrocytomas, imaging appearance often reflects the underlying grade, although not with absolute certainty. Grade 2 tumors typically show more subtle changes, often without significant contrast enhancement and with relatively limited compressive effect, reflecting slower growth. Grade 3 tumors more often demonstrate increased signal abnormality, greater infiltrative extent, and may begin to show contrast enhancement, indicating higher biological activity. Grade 4 IDH-mutant astrocytomas usually display more aggressive imaging features, such as heterogeneous contrast enhancement, areas of necrosis, and more pronounced edema and mass effect, although their overall behavior still differs from glioblastoma. Grade 4 IDH-mutant astrocytomas most commonly involve the cerebral hemispheres, particularly the frontal lobes, but they do not show a specific predilection for a particular subregion. Compared to glioblastoma (IDH-wildtype), they are less likely to present with classic “butterfly” growth across the corpus callosum, reflecting differences in biological behavior and patterns of infiltration.

Image: Left: A Grade 2 astrocytoma (no contrast uptake). Right: A more aggressive Grade 4 tumor, which appears bright white after contrast injection and shows a dark area of necrosis in the middle.

It is important to understand that these imaging differences represent a spectrum rather than strict categories, and MRI alone cannot definitively determine tumor grade. The same lesion may appear relatively indolent at one stage and more aggressive later, reflecting biological progression over time. For this reason, MRI findings must always be interpreted together with histopathological and molecular analysis, rather than used in isolation.

Advanced MRI Techniques

Depending on location and surgical planning, advanced imaging may be used:

• functional MRI (fMRI) to identify speech and motor cortex
• MR tractography (DTI) to map critical white matter tracts
• MR spectroscopy (MRS) to assess metabolic behavior
• MR perfusion to help characterize aggressiveness
• MR angiography (MRA) to assess vascular relationships

These tools refine the map, but they do not replace tissue diagnosis.

Differential Diagnosis

Depending on MRI appearance, astrocytoma may need to be distinguished from:

• oligodendroglioma
• glioblastoma
• primary CNS lymphoma
• metastases
• abscess
• tumefactive demyelinating lesions (such as multiple sclerosis)
• radiation necrosis or treatment-related changes

For that reason, no important management decision should rely on a radiology report alone. The images themselves must be reviewed directly by an experienced neurosurgeon and correlated with the pathology and molecular data.

In many cases, MRI already provides a reasonable orientation as to whether a lesion is likely an astrocytoma and even suggests its approximate grade. However, even at the time of surgery, the exact diagnosis is often not fully certain until definitive histopathology is available. Intraoperative (extemporaneous) pathology can help guide the procedure, mainly by indicating tumor type or level of malignancy, but it is typically only an orientation and not a final diagnosis. For that reason, no important management decision should rely on a radiology report alone—the images must be reviewed directly and correlated with pathology and molecular findings.

Why Histopathology Remains the Gold Standard

Imaging can strongly suggest astrocytoma, but definitive diagnosis requires tissue obtained through:

• surgical resection
• or biopsy

The pathology report evaluates:

• Cellular atypia: Abnormal cell structure
• Mitotic activity: Rate of cell division
• Cellular density: Concentration of tumor cells
• Necrosis: Areas of tissue death
• Microvascular proliferation: New blood vessel growth
• Immunohistochemical markers: Genetic and protein profiling

Markers such as:

• GFAP
• OLIG2
• ATRX
• p53
• Ki-67

help define the tumor’s astrocytic nature and biological activity.

Molecular Diagnosis Is Essential

Modern diagnosis does not stop at microscopy.

The final integrated diagnosis requires molecular analysis, especially:

• IDH mutation status
• In many treatment contexts, MGMT promoter methylation is also assessed. This does not define the tumor type, but it helps predict how well chemotherapy may work. If the MGMT gene is “switched off” (methylated), tumor cells are less able to repair damage caused by chemotherapy such as temozolomide, and treatment is more likely to be effective. If the MGMT gene remains active (unmethylated), tumor cells can better repair this damage, and the response to treatment may be weaker.

These findings do not merely decorate the report. They explain why some astrocytomas behave more indolently, why others progress more rapidly, and how treatment expectations should be framed.

Astrocytoma and Headache — Is the Tumor Always the Cause?

Headache is a common symptom in the general population and does not automatically indicate that a brain tumor is the cause.

In patients with astrocytoma, headache is more likely to be related to the tumor when there is:

• significant tumor size
• surrounding edema
• increased intracranial pressure
• mass effect

However, in patients with small, non-enhancing, or diffuse lesions without mass effect, headache is often unrelated to the tumor.

Many patients have primary headache disorders such as:

• tension-type headache
• migraine
• cervicogenic headache

These conditions are very common and may coexist with an incidental brain tumor.

For this reason, the presence of headache alone is usually not a sufficient indication for surgical treatment of an otherwise stable astrocytoma.

Careful clinical evaluation is required to determine whether the tumor is actually responsible for the symptoms.

Astrocytoma and Seizures — When Is the Tumor the Cause?

Seizures may be the first symptom of an astrocytoma, particularly when the tumor involves or is close to the cerebral cortex. However, it is important to understand that not every seizure in a patient with astrocytoma is necessarily caused by the tumor. Epilepsy can occur independently, and a brain lesion may be an incidental finding.

For this reason, it is essential to evaluate whether the tumor is truly responsible for seizure activity.

This assessment typically includes:

• correlation between tumor location and cortical areas involved in seizures
• EEG findings and their spatial relation to the lesion
• presence of surrounding edema or cortical irritation
• clinical seizure pattern

When seizures are clearly related to the tumor:

• surgical treatment may significantly reduce seizure frequency
• in some patients, seizures may stop completely

However, when seizures are well controlled with medication and the tumor shows no signs of progression, immediate surgery may not always be necessary.

Treatment of Astrocytoma in Adults

Once a brain tumor is diagnosed, treatment decisions are ideally made in a multidisciplinary neuro-oncology setting, integrating:

• MRI findings
• pathology
• molecular markers
• neurological function
• functional status
• age
• and realistic surgical benefit

The Main Treatment Categories

Treatment may include:

• observation
• symptomatic treatment
• surgery
• radiotherapy
• chemotherapy

The correct combination depends entirely on the specific astrocytoma subtype and clinical context. The treatment strategy is based on the latest neuro-oncological clinical guidelines and the patient’s overall health.

After evaluation by a multidisciplinary neuro-oncology team (tumor board), the treatment decision may be one of the following:

• Surgical resection followed by radiotherapy and chemotherapy (Temozolomide), which is the most common approach when surgery is feasible
• Biopsy followed by radiotherapy and chemotherapy when safe resection is not possible or would not provide meaningful benefit
• Structured observation (active surveillance) in carefully selected cases, when the lesion is stable on serial MRI, symptoms are minimal or well controlled, and there is no urgent need for immediate intervention, with the understanding that diagnosis cannot be definitively confirmed without tissue analysis and that treatment may become necessary if progression occurs
• Symptomatic (palliative) treatment only in patients with poor functional status or extensive disease where active treatment would not improve quality of life

Treatment of Astrocytoma According to Grade (IDH-mutant)

Although general treatment principles apply to all astrocytomas, the actual strategy differs significantly between grade 2, 3, and 4 tumors. These are not separate diseases, but different stages of biological aggressiveness within the same spectrum.

Grade 2 IDH-mutant Astrocytoma Treatment

In grade 2 astrocytoma, surgery is often the first and most important step when it is safely feasible.

These tumors infiltrate surrounding brain tissue, which means that surgical removal is not based on finding a cleavage plane, but on removing as much MRI-visible abnormal tissue (on T2/FLAIR sequences) as safely possible. As a result, surgery in grade 2 astrocytoma may involve resection may extend to resection of an entire anatomical region or lobe when functionally safe, guided by neuronavigation and functional mapping.

However, surgery is not always appropriate. It may be avoided or limited when:

• the tumor involves eloquent cortex (speech, motor, vision)
• the expected neurological deficit would outweigh benefit
• the lesion is diffuse and not surgically accessible
• functional status is already compromised

In such cases, biopsy may be the more appropriate initial step.

After surgery, further management depends on the overall risk profile. Lower-risk patients — typically younger individuals, those with more complete tumor removal, preserved neurological function, and stable imaging — may be managed with observation and regular MRI follow-up. In contrast, patients with higher-risk features such as residual tumor, tumor growth over time, or the development of symptoms (including seizures or neurological decline) are more likely to require active treatment, most often with radiotherapy, with or without chemotherapy, depending on the clinical context.

In selected patients, particularly those with higher-risk features, Temozolomide (Temodar) is often used. It can be given concurrently with radiotherapy as a radiosensitizer, and/or as adjuvant chemotherapy after completion of radiation, in cyclic regimens. The exact use of Temozolomide depends on factors such as patient age, extent of resection, tumor behavior over time, and overall clinical context.

The goal of this combined approach is not to eliminate the disease completely, but to control residual microscopic tumor, delay progression, and preserve neurological function for as long as possible.

The key principle is that grade 2 astrocytoma often follows a long clinical course, but is not biologically benign. Treatment decisions are therefore based on timing, risk, and functional impact, not on the diagnosis alone.

Grade 3 IDH-mutant Astrocytoma Treatment

In the absence of contraindications, surgical resection is the primary approach; otherwise, a biopsy is performed. In both cases, adjuvant therapy is subsequently indicated.

The goal of surgery is to remove as much of the tumor as safely possible, while protecting the normal function of the brain. On an MRI scan, the tumor is typically visible in two ways: as a bright spot on the contrast-enhanced scan (representing the most active part of the tumor) and as a white area on the T2/FLAIR scan (representing the zone where tumor cells have spread into the surrounding brain tissue).

The surgeon always aims to remove the contrast-enhancing part first, as this is the most biologically aggressive portion of the tumor. However, in some patients with this type of tumor, there may be little or no contrast enhancement at all — meaning the tumor does not show up clearly on the contrast scan. In those cases, the white area on the T2/FLAIR scan becomes the main guide for surgery, similar to how lower-grade brain tumors are approached.

When it is safe to do so, the surgeon will also attempt to remove as much of the surrounding abnormal tissue as possible — the area that appears white on T2/FLAIR. How far this resection extends depends not on the scan alone, but on how close the tumor is to areas of the brain responsible for movement, speech, or other vital functions.

It is important to understand that this type of tumor does not have sharp edges. Tumor cells spread diffusely into the surrounding brain, which means complete removal of every tumor cell is not possible. The goal of surgery is therefore not to achieve a perfect anatomical removal, but to reduce the tumor burden as much as safely possible — which makes subsequent treatments such as radiation and chemotherapy more effective, and helps the patient maintain their quality of life.

Grade 3 astrocytoma represents a more active phase of the disease and usually requires postoperative oncologic treatment.

After surgery (or biopsy if resection is not feasible), treatment most often includes:

• radiotherapy
• Temozolomide chemotherapy (concurrent and/or adjuvant)

This combined approach is conceptually similar to the treatment used in grade 4 tumors, but the overall strategy, timing, and expected disease course differ, reflecting the distinct biology of grade 3 astrocytoma.

Grade 4 IDH-mutant Astrocytoma

In the absence of contraindications, surgical resection is the primary approach; otherwise, a biopsy is performed. In both cases, adjuvant therapy is subsequently indicated.

Grade 4 IDH-mutant astrocytoma represents the most aggressive end of this spectrum and is treated more similarly to high-grade gliomas, although it remains biologically distinct from glioblastoma.

In most patients, treatment includes:

• maximal safe surgical resection (when feasible)
• followed by radiotherapy combined with Temozolomide
• and adjuvant Temozolomide

The rationale is the same as in other high-grade diffuse gliomas:

The goal of surgery is to remove as much of the tumor as safely possible, while protecting the normal function of the brain.

In grade 4 IDH-mutant astrocytoma, the tumor typically shows a clearly visible bright area on the contrast-enhanced MRI scan, representing the most active and aggressive part of the tumor. Unlike glioblastoma, however, this tumor carries a specific genetic change — the IDH mutation — which makes it biologically less aggressive than glioblastoma, despite sharing the same grade 4 classification. This distinction matters, because these patients tend to be younger and have a longer life expectancy, which makes preserving brain function an especially important part of the surgical plan.

The surgeon always aims to remove the contrast-enhancing tumor as completely as possible. When it is safe to do so, surgery may also extend into the surrounding white area visible on the T2/FLAIR scan, where tumor cells have infiltrated the surrounding brain tissue beyond the visible tumor core.

How far this resection extends depends not on the scan alone, but on how close the tumor is to areas responsible for movement, speech, memory, or other vital functions. In some locations, a more extensive removal is safely achievable. In others, preserving function takes priority.

As with all diffuse gliomas, this tumor does not have sharp edges. Tumor cells spread into the surrounding brain in a way that cannot be fully captured on any scan, and complete removal of every tumor cell is not possible. The goal of surgery is therefore not a perfect anatomical removal, but maximal safe cytoreduction — reducing the tumor burden as much as possible to make subsequent radiation and chemotherapy more effective, and to help the patient maintain their quality of life for as long as possible.

At this stage, more frequently than in Grade 2 or 3 cases, contraindications may render surgical resection non-indicated. In such instances, the protocol shifts to biopsy followed by adjuvant therapy. In the most advanced clinical presentations, where even biopsy is unfeasible, the focus remains solely on symptomatic palliative care—a management strategy similar to that employed for Glioblastoma (GBM).

Key Clinical Principle

The presence of a tumor does not automatically define the treatment.

Treatment intensity increases with:

• tumor grade
• growth behavior
• clinical symptoms
• and risk of progression

Two patients with “astrocytoma” may receive completely different treatments depending on these factors.

Symptomatic Treatment in Brain Astrocytoma

Symptomatic treatment addresses the effects of the tumor on the brain rather than the tumor biology itself.

This may include:

• Dexamethasone to reduce edema
• anti-epileptic drugs for seizure control
• analgesics
• anti-nausea medication
• supportive treatment for confusion or agitation

Improvement after steroids usually reflects reduction of edema and mass effect, not elimination of the tumor.

Surgical Management of Astrocytoma in Adults

Surgery plays several possible roles:

• obtaining tissue for diagnosis
• reducing tumor burden
• relieving mass effect
• improving or stabilizing neurological function
• creating the best conditions for further treatment

The principle is not maximal removal at any cost, but maximal safe resection.

The most important question is not simply whether surgery is technically possible, but what is realistically gained by surgery in this specific patient?

That depends on:

• tumor grade
• tumor location
• proximity to eloquent cortex
• depth
• infiltrative extent
• preoperative neurological status
• Karnofsky Performance Status (KPS)
• response to steroids
• age and overall condition

Surgical treatment involves a craniotomy (the surgical opening of the skull). The surgeon then navigates through the brain tissue to access the tumor, often using neuronavigation to guide the path. Once reached, the goal is to remove as much of the tumor as safely possible—a process known as maximal safe resection. The surgical goal for resection is defined by the tumor grade, following the criteria described in the chapters above. The primary goal is to maximize tumor removal while safeguarding neurological function. This balance is critical, as the preservation of a high Karnofsky Performance Status (KPS) is just as vital for the patient’s prognosis as the extent of the resection itself. A stable KPS not only ensures functional independence but also determines the patient’s eligibility for essential post-operative therapies like radiation and chemotherapy.

Image: The image illustrates a craniotomy. Both the skin incision and the skull opening are performed within the hair-bearing area of the scalp. The dura is opened to expose the brain as part of the surgical approach to the tumor. After the procedure, the dura is closed with stitches, the bone flap is secured, and the scalp is reconstructed, ensuring no cosmetic defect remains after healing.

Modern Surgical Technologies in Brain Astrocytoma Surgery

The goal of modern neurosurgery is to maximize tumor removal while leaving healthy brain tissue untouched. To achieve this, several advanced technologies are used to guide the surgeon in real-time.

Neuronavigation and Intraoperative Imaging

Think of neuronavigation as „GPS for the brain.“ By synchronizing the patient’s head with their MRI scans, this system allows the surgeon to see the exact position of their instruments inside the brain with sub-millimeter precision. This is especially vital for reaching deep-seated tumors or defining the irregular edges of a astrocytoma. In some centers, intraoperative MRI or Ultrasound is used to update these „maps“ during surgery as the brain shifts.

Image: Preoperative preparation for brain tumor surgery using MRI-guided neuronavigation in the operating room.

Fluorescence-Guided Surgery (5-ALA)

Astrocytoma cells often blend in with healthy brain tissue, making them hard to see under standard white light. With this technology, the patient drinks a special liquid (5-ALA) a few hours before surgery. Under a specific blue light on the surgical microscope, the tumor cells glow a bright pink/violet color. This „glow-in-the-dark“ effect helps the surgeon identify and remove hidden tumor clusters that would otherwise be invisible, significantly increasing the likelihood of a complete resection.

Intraoperative Neurophysiological Monitoring (IONM)

This acts as a continuous „early warning system“ for the brain’s function. While the patient is asleep, specialized technicians monitor electrical signals passing through the brain. If the surgeon’s instruments get too close to a vital pathway—such as the nerves controlling movement or sensation—the system provides an immediate alert. This allows the surgeon to stop or change direction before any permanent neurological damage occurs.

Awake Craniotomy in Eloquent Cortex

For tumors located in „eloquent“ areas (the centers for speech, language, or complex movement), an awake craniotomy is the safest option. Although the patient is awake for part of the procedure, they feel no pain because the brain itself has no pain receptors and local anesthesia is used for the scalp. By having the patient talk, count, or move their fingers during the resection, the surgeon can map the brain in real-time. This ensures the tumor is removed as aggressively as possible without damaging the patient’s ability to communicate or move.

Note to Patients: Not every surgery requires all of these technologies. Your neurosurgical team will select the specific tools that are most appropriate for the size and location of your tumor to ensure the safest and most effective outcome.

Read more about potential complications following craniotomy and open brain surgery on this page.

Not every operation requires all of these tools. The goal is always to maximize safe tumor removal while preserving meaningful neurological function.

When Biopsy Is Preferred Over Surgery

Biopsy is medically appropriate when resection would be too risky or would not provide meaningful benefit.

This may apply when there is:

• grade 4 and sometimes 3
• deep-seated location
• eloquent cortex involvement
• diffuse bilateral infiltration
• poor functional status
• or a situation where surgery would not improve the overall therapeutic path

Biopsy is not a “lesser” treatment. It is often the correct step needed to establish diagnosis and plan the proper oncologic strategy.

Types of Brain Biopsy and What Patients Should Expect

In most cases, biopsy is performed as a stereotactic (needle) biopsy, which is a minimally invasive procedure.

This can be done using either:

• a frame-based system (a rigid frame attached to the head for maximum precision), or
• a frameless (neuronavigation-guided) system, which uses advanced imaging and tracking without a fixed frame

Both approaches are widely used today and provide high accuracy, with the choice depending on the tumor location, institutional preference, and surgical planning.

The procedure is usually performed:

• under general anesthesia (the patient is asleep), or
• in selected cases under local anesthesia with sedation, especially with frame-based systems

Open biopsy (during a craniotomy) is less commonly performed as a separate procedure, because if open surgery is undertaken, surgeons typically aim for maximal safe resection rather than biopsy alone.

From a patient’s perspective, stereotactic biopsy is generally:

• shorter and less invasive than tumor removal surgery
• associated with faster recovery
• focused on diagnosis rather than immediate treatment

Radiotherapy and Chemotherapy for Astrocytoma in Adults (Grade 2-4)

Adjuvant therapy (radiotherapy and chemotherapy) is used to control residual microscopic disease that cannot be removed surgically. Its role and intensity increase with tumor grade.

Radiotherapy does not target only the visible tumor. In most cases, the treatment area includes the tumor itself and a surrounding zone of brain tissue that may contain microscopic tumor infiltration, often corresponding to MRI changes (such as FLAIR). This surrounding margin is usually on the order of up to about 1–2 cm, although the exact extent is individualized based on tumor type, location, and planning protocols. External beam radiotherapy is the standard approach, delivered in multiple sessions (fractions) over several weeks. Modern techniques (such as IMRT or stereotactic radiotherapy) allow precise targeting of the tumor while reducing exposure to surrounding healthy brain tissue.

Grade 2 (IDH-mutant)

Adjuvant therapy is not always required immediately after surgery.

It is typically recommended when there is:

• residual tumor with high-risk features
• documented growth on follow-up MRI
• or development of symptoms

When indicated, treatment usually includes:

• radiotherapy, most commonly delivered as external beam radiation to a total dose of 50–54 Gy over approximately 5–6 weeks
• Temozolomide (Temodar) may be added in selected higher-risk patients, either concurrently with radiotherapy and/or as adjuvant therapy

Grade 3 (IDH-mutant)

In grade 3 astrocytoma, adjuvant therapy is most often recommended after surgery or biopsy.

Treatment typically includes:

• radiotherapy, delivered to a total dose of 60 Gy in standard daily fractions over approximately 6 weeks
• Temozolomide chemotherapy, given concurrently with radiotherapy and/or as adjuvant treatment

This approach reflects the more aggressive biological behavior compared to grade 2 disease.

Grade 4 (IDH-mutant)

In grade 4 astrocytoma, adjuvant therapy is considered standard and is usually initiated after surgery or biopsy.

Treatment most commonly follows a combined protocol similar in structure to the Stupp regimen:

• radiotherapy to a total dose of 60 Gy (2 Gy per fraction over 6 weeks)
• concurrent Temozolomide administered daily during radiotherapy (typically 75 mg/m²)
• followed by adjuvant Temozolomide, given in cycles (commonly 150–200 mg/m² for 5 days every 28 days, for 6 or more cycles depending on tolerance and response)

Image: Combined radiotherapy and Temozolomide (TMZ) treatment schedule used in high-grade astrocytoma. During the first 6 weeks, radiotherapy is delivered together with daily Temozolomide (concurrent phase), followed by cyclic adjuvant Temozolomide treatment. Although this approach is structurally similar to glioblastoma protocols, astrocytoma, IDH-mutant, grade 4 represents a biologically distinct disease with generally more favorable outcomes.

In some treatment strategies, especially in selected higher-risk patients, PCV chemotherapy (a combination of procarbazine, lomustine, and vincristine) may be used instead of or in addition to Temozolomide.

Observation in Adult Astrocytoma (Selected Cases Only)

In rare situations, a lesion that appears stable over a long period of time — for example, when prior imaging suggests that it has been present for many years without significant change — may be managed with careful follow-up rather than immediate intervention.

However, it is important to understand that in adults, a diagnosis of astrocytoma cannot be confirmed without tissue analysis. Imaging alone may strongly suggest a diffuse glioma, but it cannot definitively determine tumor type or biological behavior.

For this reason, observation is typically considered only when:

• the lesion shows no signs of progression on serial MRI
• symptoms are minimal or well controlled
• surgical intervention carries a meaningful functional risk
• and there is no urgent need for immediate histological confirmation

In such cases, management is based on close monitoring, with the understanding that intervention may become necessary if the lesion changes over time.

Prognosis and Survival for Astrocytoma in Adults

Prognosis in astrocytoma varies widely because astrocytoma is not one disease.

The most important prognostic factors include:

• exact diagnosis
• IDH status
• grade
• age
• functional status
• extent of safe resection
• tumor location
• response to treatment
• and overall biological behavior over time

General Principle

The more favorable end of the spectrum includes:

• pediatric grade 1 tumors
• circumscribed lesions
• IDH-mutant diffuse astrocytomas with slower behavior
• younger, functionally independent patients
• and tumors that can be safely resected extensively

The less favorable end includes:

• rapidly progressive tumors
• grade 4 disease
• poor functional status
• limited resectability
• and aggressive biological behavior

Broad Survival Orientation for IDH-mutant Astrocytoma

Because patients almost always ask for numbers, it is reasonable to discuss broad ranges honestly, while emphasizing that these are not personal predictions.

For many adult IDH-mutant astrocytomas:

• Grade 2 often has a long course, and median survival in modern series may extend roughly into the 8–15+ year range in favorable settings
• Grade 3 often remains a long-survival disease compared with glioblastoma, with median survival often in the 5–10 year range
• Grade 4 IDH-mutant astrocytoma generally has a better prognosis than glioblastoma, although it remains a serious, life-limiting malignant disease. Median survival in glioblastoma is typically around 12–15 months, whereas in grade 4 IDH-mutant astrocytoma it often extends to several years, commonly in the range of approximately 2–4 years depending on clinical and molecular factors.

These are broad, context-dependent ranges. Real outcome varies substantially with age, surgery, molecular profile, and treatment response.

Functional Prognosis Matters Too

In astrocytoma, survival should not be understood only in calendar terms. Patients care about:

• independence
• speech
• mobility
• cognition
• self-care
• and quality of life

A treatment strategy should therefore be judged not only by whether it extends life, but whether it preserves meaningful function.

Bottom Line

• some astrocytomas have a very long course
• recurrence and progression over time remain common
• prognosis depends on biology, not just grade
• IDH-mutant tumors usually do better than IDH-wildtype glioblastoma
• honest counseling requires numbers, context, and limits

Management of Recurrence in Astrocytoma (Grades 2–4)

Recurrence in astrocytoma is expected over time, but it does not represent a single situation. Management depends on tumor grade, time to progression, imaging pattern, and functional status.

The key clinical challenge is not only detecting recurrence, but determining:

• whether the lesion represents true tumor progression or treatment-related change
• whether surgery will provide meaningful benefit
• and whether further oncologic treatment is justified

True Tumor Recurrence vs Radiation Necrosis

After radiotherapy, new or increasing MRI changes do not automatically mean tumor recurrence.

Three possibilities must always be considered:

• True tumor progression
• Pseudoprogression (early treatment effect)
• Radiation necrosis (late treatment-related injury)

These conditions may appear similar on MRI:

• contrast enhancement
• surrounding edema
• mass effect
• clinical deterioration

How to Distinguish Recurrence from Radiation Necrosis

No single test is definitive. Diagnosis is based on a combination of:

• MRI evolution over time (progressive vs stable or fluctuating changes)
• advanced imaging (perfusion MRI, MR spectroscopy, sometimes PET)
• clinical course (speed of deterioration, steroid response)

Typical patterns:

• Tumor recurrence → progressive growth, increasing enhancement, worsening symptoms
• Radiation necrosis → may fluctuate, often steroid-responsive, may appear months to years after RT

However, in many cases, imaging remains inconclusive, and decision-making must rely on overall clinical context.

When Reoperation Is Indicated

Reoperation is not automatic and is only considered when it is expected to provide real clinical benefit.

Reoperation is most appropriate when:

• the patient has good functional status (KPS ≥70)
• the lesion is well localized and surgically accessible
• there is significant mass effect causing symptoms
• a meaningful volume of tumor can be removed
• the patient is expected to tolerate recovery and further therapy

In this setting, surgery may:

• reduce tumor burden
• relieve intracranial pressure
• improve or stabilize neurological function
• provide tissue for updated diagnosis (progression vs transformation)

When Reoperation Is Not Appropriate

Surgery is usually avoided when:

• low functional status (KPS <60)
• diffuse or bilateral disease
• deep or eloquent location with high risk of deficit
• limited expected benefit from cytoreduction

In these cases, surgery may worsen quality of life without improving outcome.

Reoperation in Radiation Necrosis

Radiation necrosis is not a tumor, but it can produce significant mass effect and neurological deterioration.

Surgery may be indicated when:

• symptoms are severe and progressive
• steroids are ineffective or not tolerated
• imaging cannot exclude tumor recurrence
• removal would significantly reduce mass effect

In this situation, surgery is performed:

• to relieve pressure
• to improve neurological function
• to confirm diagnosis

Importantly, functional improvement after surgery is often more pronounced in radiation necrosis than in tumor recurrence, because no active tumor remains.

Role of Adjuvant Treatment at Recurrence

Further treatment depends on tumor biology and prior therapy.

Options may include:

• repeat radiotherapy (selected cases only)
• chemotherapy (Temozolomide rechallenge or alternative protocols)
• targeted or antiangiogenic therapy (e.g., Bevacizumab)
• clinical trials

Key principles:

• treatment is individualized
• prior treatments and response matter
• benefit must be balanced against toxicity and functional decline

Grade-Specific Considerations

Although principles overlap, recurrence behaves differently across grades:

• Grade 2 (IDH-mutant)
  • progression may be slow
  • reoperation often considered for growth or malignant transformation
  • long-term strategy is critical
• Grade 3 (IDH-mutant)
  • higher likelihood of progression
  • reoperation considered when localized recurrence and functional reserve exist
  • systemic therapy often required
• Grade 4 (IDH-mutant astrocytoma / glioblastoma)
  • recurrence is expected
  • reoperation only in selected cases
  • treatment often focuses on disease control and function preservation

Core Clinical Principle

Management of recurrence is not based on imaging alone.

It requires integration of:

• MRI dynamics over time
• neurological status
• tumor location and resectability
• prior treatment
• expected benefit vs risk

Two patients with “recurrence” may require completely different decisions. Both called “astrocytoma” may require completely different decisions.

Experimental and Emerging Therapies in Astrocytoma

Many patients investigate new or experimental treatment options, especially in cases of progression.

These may include:

• clinical trials (novel drugs, targeted therapies)
• immunotherapy approaches
• vaccine-based treatments
• experimental drug combinations

While these strategies are scientifically important, it is essential to understand:

• most remain investigational
• individual benefit is uncertain
• they do not replace standard treatment

The main risks include:

• loss of time
• treatment-related toxicity
• unrealistic expectations

A balanced approach is required:

• exploration of new options is reasonable
• but decisions must remain grounded in clinical reality

If you are considering an experimental treatment within a clinical trial or an ‘off-label’ therapy, you may request an independent second opinion to evaluate the potential benefits and risks of such an approach.

Why Do Experts Sometimes Disagree About the Best Treatment?

It is not uncommon for different specialists to recommend different strategies for the same astrocytoma. This does not mean that someone is wrong — it reflects the complexity of the disease and the fact that in many situations there is no single correct treatment.

Tumors can behave differently in each patient, even with the same diagnosis. Specialists may prioritize different goals — maximal tumor removal, preservation of neurological function, or quality of life. In addition, guidelines are not always identical, and medical knowledge is evolving, especially with the growing role of molecular markers. Finally, patient preferences play an important role in every decision.

These differences become most visible in key treatment decisions:

Surgery vs Biopsy — When Is Tumor Removal Recommended

When the tumor can be removed with acceptable neurological risk, many specialists recommend maximal safe resection. However, if the tumor involves deep or critical brain areas, the risk of surgery may outweigh the benefit, and a biopsy followed by oncological treatment may be preferred.

When It May Be Safer Not to Operate Immediately

Not all astrocytomas require immediate surgery. In selected cases, especially with slower growth or mild symptoms, some specialists recommend observation or delayed intervention, while others favor earlier treatment to reduce the risk of progression.

Extent of Resection — How Much Tumor Should Be Removed

Even when surgery is indicated, opinions may differ. Some aim for maximal safe resection, while others take a more conservative approach near critical brain structures. The key question is how much can be safely removed, not simply how much can be removed.

Risks of Surgery vs Risks of Tumor Progression

Decisions often involve balancing immediate surgical risk against the risk of tumor progression. Some prioritize avoiding neurological deficits, while others emphasize early tumor control.

Role of Molecular Factors in Treatment Decisions

Molecular markers such as IDH status increasingly influence strategy. In some cases they support a more aggressive approach, while in others they justify a more conservative plan.

When a Second Opinion May Be Helpful

If you have received different recommendations — or if you are unsure which path is best — seeking an additional expert opinion can be valuable.

A second opinion may help you:

• understand why recommendations differ
• confirm whether the proposed treatment is appropriate
• explore alternative strategies that may not have been discussed
• make a more confident and informed decision

If you would like an independent review of your case, you can request a detailed evaluation here:
https://neurohirurgija.in.rs/en/second-opinion-in-neurosurgery-trusted-insight/

Frequently Asked Questions About Brain Astrocytoma